Literature DB >> 23729705

Vertebra collapse due to primary amyloidosis causing neurological compromise.

Hiroyuki Yoshihara1, Kenya Nojiri, Mariko Yabe, Takeshi Takahata.   

Abstract

In primary amyloidosis (AL), a fibrillar protein (amyloid light chain) is deposited in many organs; however, it is rare to have involvement of the vertebral bodies. Multiple myeloma is a well-known systemic amyloid disease that frequently has vertebral involvement. However, the pathology of vertebral involvement of these two clinical entities differs significantly. We report a patient with L4 vertebral collapse because of primary AL, causing neurological compromise that improved with surgical treatment. Deposition of amyloid and following demineralisation caused the vertebral collapse. Primary AL needs to be taken into consideration as a cause of pathological vertebral fracture.

Entities:  

Mesh:

Year:  2013        PMID: 23729705      PMCID: PMC3702817          DOI: 10.1136/bcr-2013-009075

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  11 in total

1.  Bone and joint involvement in primary amyloidosis.

Authors:  R C Hannon; C Limas; O S Cigtay; H L Twigg
Journal:  J Can Assoc Radiol       Date:  1975-06

2.  Superior survival in primary systemic amyloidosis patients undergoing peripheral blood stem cell transplantation: a case-control study.

Authors:  Angela Dispenzieri; Robert A Kyle; Martha Q Lacy; Terry M Therneau; Dirk R Larson; Matthew F Plevak; S Vincent Rajkumar; Rafael Fonseca; Philip R Greipp; Thomas E Witzig; John A Lust; Steven R Zeldenrust; Denise S Snow; Susan R Hayman; Mark R Litzow; Dennis A Gastineau; Ayalew Tefferi; David J Inwards; Ivana N Micallef; Stephen M Ansell; Luis F Porrata; Michelle A Elliott; Morie A Gertz
Journal:  Blood       Date:  2004-01-22       Impact factor: 22.113

3.  Improvement in quality of life of patients with AL amyloidosis treated with high-dose melphalan and autologous stem cell transplantation.

Authors:  David C Seldin; Jennifer J Anderson; Vaishali Sanchorawala; Karim Malek; Daniel G Wright; Karen Quillen; Kathleen T Finn; John L Berk; Laura M Dember; Rodney H Falk; Martha Skinner
Journal:  Blood       Date:  2004-05-20       Impact factor: 22.113

4.  Vertebral body collapse due to primary amyloidosis.

Authors:  M Brzeski; J G Fox; J M Boulton-Jones; H A Capell
Journal:  J Rheumatol       Date:  1990-12       Impact factor: 4.666

Review 5.  The systemic amyloidoses.

Authors:  R H Falk; R L Comenzo; M Skinner
Journal:  N Engl J Med       Date:  1997-09-25       Impact factor: 91.245

Review 6.  Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): a consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis, Tours, France, 18-22 April 2004.

Authors:  Morie A Gertz; Ray Comenzo; Rodney H Falk; Jean Paul Fermand; Bouke P Hazenberg; Philip N Hawkins; Giampaolo Merlini; Philippe Moreau; Pierre Ronco; Vaishali Sanchorawala; Orhan Sezer; Alan Solomon; Giles Grateau
Journal:  Am J Hematol       Date:  2005-08       Impact factor: 10.047

7.  Primary amyloidosis with unusual bone involvement: reversibility with melphalan, prednisone, and colchicine.

Authors:  A Schattner; D Varon; L Green; N Hurwitz; Z Bentwich
Journal:  Am J Med       Date:  1989-03       Impact factor: 4.965

8.  Primary systemic amyloidosis: clinical and laboratory features in 474 cases.

Authors:  R A Kyle; M A Gertz
Journal:  Semin Hematol       Date:  1995-01       Impact factor: 3.851

9.  A trial of three regimens for primary amyloidosis: colchicine alone, melphalan and prednisone, and melphalan, prednisone, and colchicine.

Authors:  R A Kyle; M A Gertz; P R Greipp; T E Witzig; J A Lust; M Q Lacy; T M Therneau
Journal:  N Engl J Med       Date:  1997-04-24       Impact factor: 91.245

Review 10.  Amyloidosis (AL). Clinical and laboratory features in 229 cases.

Authors:  R A Kyle; P R Greipp
Journal:  Mayo Clin Proc       Date:  1983-10       Impact factor: 7.616

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.